314 Index Name Paper ref. Name Paper ref. Aalkjær, C Tue 038, Wed 221, Wed 433 Aalling, M Tue 161 Ab Wahab, MS Mon 147, Mon 333 Abacioglu, N Mon 366 Abad, S Wed 177 Abasnejad, M Tue 165 Abass, K Thu 348 Abbasi, S Thu 113 Abdallah, DM Wed 382 Abdel Aziz, H Tue 464 Abdel Razek, H Tue 264 Abdel-Aziz, H Wed 382 Abdel-Maksoud, S FC06.2.6 Abdel-Rahman, SM FC10.2.4 Abdel-tawab, AM-D Mon 252 Abdel-Tawab, M Thu 010 Abdourahman, A Thu 427 Abdul Hamid, R Wed 323 Abdul Sattar, MZ FC05.1.5 Abduljalil, K Mon 384 Abdulla, MH FC05.1.5 Abdullah, AD Tue 408 Abdullah, N Mon 389 Abdullah, NA YI.04, FC05.1.5 Abdullah, NR Thu 328 Abdullah, WZW Mon 361 Abduzaimovic, D Wed 171, Wed 004 Abe, K Thu 038 Abe, M Tue 216 Abe, N Mon 255 Abedzadeh, M Thu 209 Abel, U FC18.2.6 Abernethy, D Mon 392, FC13.1.6 Abid, M Tue 002 Abi-Dargham, A FC17.1.3 Abildstrøm, SZ FC04.2.4 Able, S Mon 393, Wed 020 Able, S Mon 420 Abler, B Thu 112 Abotaleb, N Mon 188 Aboulafia, J Thu 351, Thu 352 Abu Bakar, NH Mon 107 Abu Bakar, R Mon 147, Mon 333 Aburto-Cortes, L Tue 025 Acheampong, P Mon 116, Acher, F FC11.3.6, Thu 083 Achike, F Wed 370 Achike, F I Wed 195, Wed 194 Acimovic, J Tue 383 Ackermann, S Thu 098 Acosta, G Mon 040 Acquaviva, AM Wed 307 Adam de Beaumais, T FC10.1.5 Adamicova, K Mon 293 Adamu, I Tue 011 Adamus, M Mon 081 Adaramoye, O Wed 294 Adcock, Ian M FC09.1.1 Addolorato, G FC14.2.2 Adeneye, A Tue 361 Aderaye, G FC01.4.7, Mon 018 Adeyemi, OO Wed 296, Tue 361, Wed 295 Adham, N Wed 423 Adler, A FC05.4.3 Ado, S Tue 011 Afshartous, D Wed 155 Afzal, S FC13.3.6, Tue 482, Mon 119, Mon 118, Mon 406, Tue 480 Agbani, EO Thu 272 Agha Alaie, SY Mon 002, Mon 231 Agirgol, M Mon 199 Ago, Y Tue 360, Tue 060 Agostini, S Tue 249 Agouni, A Mon 148, Wed 196 Ågren, G FC14.5.2 Agresta, A Tue 487, Mon 448, Tue 488 Agüero, J Tue 165, Thu 048 Aguero, J Tue 163 Aguiar, D FC17.5.5 Aguila, JDF Mon 038 Aguilera, R Mon 023, W04.1.3 Aguiñiga, I Tue 420 Ahluwalia, A Thu 278 Ahmad, D Tue 137 Ahmad, ED Tue 444 Ahmad, F Tue 119 Ahmad, M FC08.2.5 Ahmadi, A Wed 012 Ahmadzadehd, A Tue 251 Ahnstedt, H Wed 021 Ahokas, J Thu 348 Ai, H Thu 370, Thu 378 Aigbe, FR Wed 295 Aihara, E Thu 072 Ain-Shoka, A Tue 386 Airaksinen, AJ Thu 170 Aitta-aho, T Thu 409 Aitta-aho, T Wed 393 Ajami, A Wed 123 Ajdary, S Wed 027, Wed 437 Akagi, M Mon 253 Akagi, R Mon 253 Akahane, T Tue 311 Akaike, A Mon 432, Mon 424, Mon 464 Akaike, O Wed 371 Akamine, EH FC06.1.5 Akamine, T Mon 213 Akarasereenont, P Mon 334 Akarasereenont, P Thu 335 Akbarali, H FC12.1.5 Akdis, Cezmi A FC09.1.3 Akhtar, S FC01.4.6, Mon 151 Akiba, Y W02.1.5 Akici, A Tue 027, Mon 117 Akimoto, Y Tue 432 Akindele, A Wed 296 Akinyandenu, A Wed 144 A, Shizuo PL14 Akiyama, K Wed 414 Aklillu, E FC01.4.7, Mon 018, Tue 005, Wed 136, Tue 489 Akramiene, D Mon 403 Akritopoulos, P Tue 246 Akula, KK Wed 168 Akuwoah, GA Thu 327 Al, T Mon 264 Alabi, T Tue 361 Al-A, A Thu 338
Name Paper ref. Name Paper ref. Albarran-Juarez, J FC11.4.2, W01.2.1 Albarran-Juarez, J Wed 022 Albertioni, F Mon 055 Albrechtsen, C Tue 482 Alcántara-Vázquez del Mercado, O Thu 203 Alcaraz, MJ W09.1 Alderton, A FC03.2.6 Alefishat, E Wed 023 Alegret, M Tue 133 Aviciene, C Mon 403 Alemà, S Tue 249 Aleshcheva, G Wed 252 Alessandra, M Thu 400 Alessi, F Tue 312 Aleth, P Tue 190 Alewijnse, A Thu 258, Thu 082 Alexander, N FC11.3.2 Alexander, S Mon 404, Wed 023 Alexander, SPH Mon 282 Alfonzo, M Wed 040 Alfonzo, Marcelo J Wed 024 Alfonzo, RG Wed 024 Alfonzo-Gonzalez, M Wed 024 Alhamoruni, A Tue 460 Al-hosaini, K Wed 025 Al-Humadi, H Thu 431, A Alsinde, H FC01.1.5 A Arab, H Wed 301 Alimahomed, R Thu 085 Alisi, MA Thu 433 Al-Kashi, A FC09.5.7 Alkhawajah, AA Thu 338 Al-khrasani, M Thu 062 Al-Khrasani, M Thu 192, Allegaert, Karel FC10.4.3, Wed 001, Wed 002 Allen, M Wed 096 Allen, TJ Thu 228 Allerheiligen, SRB FC07.3.4 Alloza, JL Mon 138 Al-magableh, M Wed 255 Almaguer, D Mon 023, W04.1.3 Almeida, OF FC18.3.1 Almenar, L Tue 165, Thu 048, Tue 163 Almpani, M Thu 431 Alonso, M Wed 228, Thu 264 Alp, FI Thu 269 Alp, H Wed 312 Alp, I Tue 461 Al-Rasheed, NMI Mon 189 Alstrup, AKO FC17.4.5 Altaany, Z FC15.3.6 Altcheh, J Mon 003, Wed 003 Altcheh, J Mon 022 Altinok, A FC07.1.3 Alvarez de Mon, M Mon 254 Álvarez de Sotomayor, M Tue 118 Alvarez López, MC Mon 128 Alvarez, J-C Tue 188, Tue 189 Alvarez, M Tue 226 Álvarez, M Thu 205 Alvarez, S FC18.3.5 Alvarez-Laviada, A FC03.2.4 Alvarez-Leon, A Wed 344 Alvarez-Sala, JL Mon 374 Alves, FHF Wed 411 Alves, G Thu 169, Mon 383, Tue 407 Alves, JN Wed 342 Alves, RS Thu 374 Alves, RS Wed 297 Alves-Filho, J Mon 275 Alvey, C Mon 251 Alving, Kjell FC09.3.2 Amabeoku, G Wed 298 Amada, K Tue 132 Amadio, M Mon 152 Amagase, K Tue 262, Tue 236, W02.2.3, Tue 467, Mon 335, Mon 255, Mon 405 Amano, Y Mon 386 Amaral, F W31.4 Amberg, C Wed 071 Ambrus, N Wed 197 Amidzic, L Tue 237 Amigo, G Thu 325 Amini, M YI.07 Aminlari, M Wed 299 Ammendrup-Johnsen, I Mon 067, Mon 061 Ammer, H FC16.1.5 Amogne, W FC01.4.7, Mon 018 Amrah, SS Thu 312 Amrutka, DV Thu 106 Amrutkar, D Mon 099 Amrutkar, M Mon 336 Amundsen, R Mon 041 Amunjela, J-A Thu 315 Amyrkulova, M Tue 079 Anand, KJS Wed 006, Thu 003 Ananthan, S FC14.3.5 Anca, C Tue 190 Ancrenaz, V Mon 337 Andalib, S Mon 294 Andersen, B FC05.3.5 Andersen, CB Mon 050 Andersen, CU Tue 161 Andersen, D FC06.2.5 Andersen, DC Wed 070 Andersen, J FC13.3.6, Tue 065 Andersen, JT Mon 118, Mon 119, Mon 406 Andersen, M Wed 160 Andersen, MP Tue 303 Andersen, MV Tue 053 Andersen, N Mon 118 Andersen, NL Mon 119 Andersen, SE Tue 053 Anderson, C Tue 202 Anderson, L Wed 254 Anderson, ME FC06.4.4 Andersson, J Mon 122 Andersson, KE FC08.2.2 Andersson, M Wed 136, Mon 371 Andersson, S Wed 006 Ando, H Mon 386, Thu 268 Andó, R W19.2 Ando, Y FC07.4.3 Andrade, RJ Tue 123, Wed 109 Andrade, T Mon 298 Andrade-Lopes, AL Wed 054 Index 315
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267: FC15 Endothelium in health and dise
- Page 268 and 269: W30 Is eNOS Still a valid therapeut
- Page 270 and 271: FC16 Natural products: Past and fut
- Page 272 and 273: FC16 Natural products: Past and fut
- Page 274 and 275: FC16 Natural products: Past and fut
- Page 276 and 277: FC17 New approaches and targets in
- Page 278 and 279: FC17 New approaches and targets in
- Page 280 and 281: W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367:
364 Index Name Paper ref. Name Pape
- Page 368 and 369:
366 Index Name Paper ref. Name Pape
- Page 370 and 371:
368 Index Name Paper ref. Name Pape
- Page 372 and 373:
370 Index Name Paper ref. Name Pape
- Page 374 and 375:
372 Index Name Paper ref. Name Pape
- Page 376 and 377:
374 Index Name Paper ref. Name Pape
- Page 378 and 379:
376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor